The aim of the current study was to evaluate the outcomes of the surgical excision of the ocular surface squamous neoplasia (OSSN) with 2 mm margins and adjuvant cryotherapy.The medical records of the subjects who were diagnosed with OSSN and treated with surgical excision with 2 mm margins and adjuvant cryotherapy at the University of Health Sciences, Abdurrahman Yurtaslan Oncology Training and Research Hospital, Department of Ophthalmology, between May 2016 and April 2022 were analyzed. According to the margin status, subjects were divided into two groups (margin positive/indeterminate or negative), and, recurrence rate, treatment methods and complications were analyzed. Out of the 26 OSSN cases, 12 were margin positive/indeterminate and 14 were negative, and, 7 showed recurrence. Of the 14 margin negative cases, 4 showed recurrences, and, of the 12 margin positive/indeterminate cases 3 showed recurrence. Of the 12 margin positive/indeterminate cases, 9 received adjuvant treatment and 1 showed recurrence. Treatments were performed by either INF alfa 2-b or recurrent cryotherapy. There was no significant difference in histopathological diagnosis, follow up period or recurrence rate between the groups (p 0.05). Complications were mild and slightly higher in cases who were treated with recurrent cryotherapy when compared with INF alfa 2-b.Adjuvant therapies reduced the recurrence rate in margin positive/indeterminate cases after excision of the OSSN with narrow margins, and margin negative cases had similar recurrence rate with margin positive/indeterminate cases. After removal of the OSSN with narrow margins, subjects should receive adjuvant therapies if the surgical margins are not negative, and, if the surgical margins were negative, then subject should be monitored closely because of the high recurrence risk of this group.
Primary Language | English |
---|---|
Subjects | Optometry |
Journal Section | Research Article |
Authors | |
Publication Date | January 3, 2024 |
Submission Date | July 11, 2023 |
Acceptance Date | October 3, 2023 |
Published in Issue | Year 2023 Volume: 40 Issue: 4 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.